Additional file 1: of Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
- Ivan Foeldvari (4578778)
- Tamàs Constantin (6731114)
- Jelena Vojinović (6731117)
- Gerd Horneff (3415988)
- Vyacheslav Chasnyk (6731120)
- Joke Dehoorne (714349)
- Violeta Panaviene (6158930)
- Gordana Sušić (6731126)
- Valda Stanevicha (6731132)
- Katarzyna Kobusinska (6731138)
- Zbigniew Zuber (4722027)
- Bogna Dobrzyniecka (6731141)
- Irina Nikishina (6731144)
- Brigitte Bader-Meunier (363218)
- Luciana Breda (6731147)
- Pavla Doležalová (6731150)
- Chantal Job-Deslandre (5049548)
- Ingrida Rumba-Rozenfelde (6731153)
- Nico Wulffraat (28328)
- Ronald Pedersen (6731156)
- Jack Bukowski (4092067)
- Bonnie Vlahos (3965894)
- Alberto Martini (8758)
- Nicolino Ruperto (3689917)
Publication date
May 2019
DOIAbstract
Table S1. Summary of missing data imputation methods for the responder analysis. Table S2. Disease activity and patient-reported outcomes (observed cases). Table S3. Outcomes specific for enthesitis-related arthritis and psoriatic arthritis (observed cases). Table S4. The most frequent TEAEs, excluding infections and injection site reactions (> 5% in any JIA subtype, by System Organ Class). Figure S1. ACR30–100 and JIA inactive disease response rates (OC vs NRI). Additional Tables (A1 to A4) and Figure A1 related to missing data imputation based on patients’ enrolment status, trial period at cut-off date, and reasons for permanent discontinuation. (DOCX 224 kb
Add to ORKG